Recursion Pharmaceuticals (RXRX) Change in Account Payables (2020 - 2026)

Recursion Pharmaceuticals' Change in Account Payables history runs 7 years deep, the most recent figure standing at $2.1 million for Q1 2026.

• Quarterly Change in Account Payables fell 43.93% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.2 million (down 147.3% YoY) and the FY2025 annual result came in at -$2.6 million, down 140.65% from the prior year.
• Change in Account Payables was $2.1 million for Q1 2026 at Recursion Pharmaceuticals, down from $4.4 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $8.1 million in Q4 2024 and bottomed at -$5.9 million in Q3 2025.
• A 5-year average of $392294.1 and a median of $695000.0 in 2022 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2022 — Change in Account Payables sank 1488.73% — and 2024, when it jumped 2662.15%.
• Recursion Pharmaceuticals' Change in Account Payables stood at $695000.0 in 2022, then sank by 145.61% to -$317000.0 in 2023, then soared by 2662.15% to $8.1 million in 2024, then slumped by 45.59% to $4.4 million in 2025, then plunged by 53.16% to $2.1 million in 2026.
• Business Quant data shows RXRX's Change in Account Payables at $2.1 million in Q1 2026, $4.4 million in Q4 2025, and -$5.9 million in Q3 2025.